Dogwood Therapeutics reports Halneuron Phase 2b progress, new SP16 license, and 2026 milestones

Dogwood Therapeutics, Inc.

Over 100 patients enrolled in Halneuron Phase 2b HALT-CINP study; interim analysis determined final sample size and methodology.
Licensed SP16 IV (royalty-free, global) for cancer neuropathy; Phase 1b fully funded by NCI development grant.
Developed chemically equivalent synthetic Halneuron for Phase 3; new IP if granted extends protection to 2046.
Milestones: final Phase 2b data Q3 2026, SP16 IND filing Q1 2026, dosing Phase 1b by mid-2026.
Completed January financing (undisclosed amount) to fund pipeline; end-of-Phase 2 FDA submission targeted late 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.